Amgen Submits Biologics License Application For Investigational BiTE Immunotherapy Blinatumomab
September 22, 2014 at 09:02 AM EDT
Amgen (NASDAQ: AMGN) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) ...
